Comparative Efficacy and Safety of Neuroprotective Therapies for Neonates With Hypoxic Ischemic Encephalopathy: A Network Meta-Analysis

Clare Yuen Zen Lee¹, Pairote Chakranon² and Shaun Wen Huey Lee¹,³,4*

¹ School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia, ² Faculty of Pharmacy, Silapakorn University, Pathom, Thailand, ³ Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO), Health and Well-being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University Malaysia, Selangor, Malaysia, ⁴ School of Pharmacy, Taylor’s University, Subang Jaya, Malaysia

Context: Several interventions are available for the management of hypoxic ischemic encephalopathy (HIE), but no studies have compared their relative efficacy in a single analysis. This study aims to compare and determine the effectiveness of available interventions for HIE using direct and indirect data.

Methods: Large randomized trials were identified from PubMed, EMBASE, CINAHL Plus, AMED, and Cochrane Library of Clinical Trials database from inception until June 30, 2018. Two independent reviewers extracted study data and performed quality assessment. Direct and network meta-analysis of randomized controlled trials was performed to obtained pooled results comparing the effectiveness of different therapies used in HIE on mortality, neurodevelopmental delay at 18 months, as well as adverse events. Their probability of having the highest efficacy and safety was estimated and ranked. The certainty of evidence for the primary outcomes of mortality and mortality or neurodevelopmental delay at 18 months was evaluated using GRADE criteria.

Results: Fifteen studies comparing five interventions were included in the network meta-analysis. Whole body cooling [Odds ratio: 0.62 (95% credible interval: 0.46–0.83); 8 trials, high certainty of evidence] was the most effective treatment in reducing the risk of mortality, followed by selective head cooling (0.73; 0.48–1.11; 2 trials, moderate certainty of evidence) and use of magnesium sulfate (0.79; 0.20–3.06; 2 trials, low certainty of evidence). Whole body hypothermia (0.48; 0.33–0.71; 5 trials), selective head hypothermia (0.54; 0.32–0.89; 2 trials), and erythropoietin (0.36; 0.19–0.66; 2 trials) were more effective for reducing the risk of mortality and neurodevelopmental delay at 18 months (moderate to high certainty). Among neonates treated for HIE, the use of erythropoietin (0.36; 0.18–0.74, 2 trials) and whole body hypothermia (0.61; 0.45–0.83; 7 trials) were associated with lower rates of cerebral palsy. Similarly, there were lower rates of seizures among neonates treated with erythropoietin (0.35; 0.13–0.94; 1 trial) and whole body hypothermia (0.64; 0.46–0.87, 7 trials).
INTRODUCTION

Neonatal hypoxic ischemic encephalopathy (HIE) is one of the most common causes of severe neurological deficit in children, affecting an estimated 15 per 10,000 live births (Graham et al., 2008; American College of Obstetricians and Gynecologists, and American Academy of Pediatrics, 2014). Several reviews have suggested that therapeutic hypothermia (both whole body and selective head) reduces mortality and improves survival with normal neurological outcome and is now a standard treatment protocol for most neonatal centers in developed countries (Edwards et al., 2010; Jacobs et al., 2013; Martinello et al., 2017). Despite this, their effectiveness is still limited, with mortality rates of approximately 10%−20% in several large trials (Jacobs et al., 2013). As a result, alternative strategies, including the use of adjuvant therapies such as xenon, allopurinol, erythropoietin, magnesium sulfate, and melatonin, have been suggested (Perrone et al., 2012). Other strategies suggested include cooling for longer periods of time, cooling at lower temperature or both (Shankaran et al., 2017).

Recently, several randomized controlled trials have examined the effects of such adjuvant therapy in neonates with HIE, yielding a complex evidence base that requires careful examination across different strategies (Bhat et al., 2009; Aly et al., 2015; Azzopardi et al., 2016; Filippi et al., 2017). However, most of these studies are relatively small and the results remains inconclusive and mixed. There are no reviews that attempted to summarize these data from large studies.

Furthermore, previous meta-analyses have often compared the efficacy of treatment within pairs of active treatment, which provides limited insights into the overall treatment hierarchy as treatment effects are estimated from two different treatment comparison only (Jacobs et al., 2013; Pauliah et al., 2013). Over the past few years, the use of network meta-analyses which allows for the simultaneous comparison of two or more interventions has increasingly been used (Lee et al., 2015; Lee et al., 2017; Bukhsh et al., 2018; Teoh et al., 2019). Network meta-analysis includes both direct and indirect comparison within a single analysis, thereby providing an integrated and more holistic conclusion, providing decision makers with a more complete evidence matrix (Watt et al., 2019). In this study, we aimed to estimate the efficacy and safety of available neuroprotective interventions for HIE who participated in randomized controlled studies.

MATERIALS AND METHODS

Search Strategy

A literature search was performed to identify for studies from inception to June 30, 2018, on the following databases: PubMed, EMBASE, CINAHL Plus, Allied and Complementary Medicines (AMED), and the Cochrane Central Register of Controlled Trials without any language restriction. We also obtained additional records by reviewing the reference list of the retrieved articles and other resources including Google Scholar, NDLTD database, and ClinicalTrials.gov. A full list of search terms can be found in eText in Supplementary Material.

Study Selection

Studies were considered eligible for inclusion if they (1) were randomized controlled studies (RCT), (2) recruited term or preterm infants (gestational age ≥35 weeks) diagnosed with HIE (3) had a control group or comparison group, (4) sufficiently powered to detect differences in the outcome of death and/or disability, and (5) the infants were given any of the following as intervention: magnesium sulfate, deferoxamine, cannabinoids, melatonin, statin, topiramate, xenon, allopurinol, erythropoietin, N-acetylcysteine, or therapeutic hypothermia; either as single intervention or adjunct therapy. Studies which had significant methodological limitations such as poor description of inclusion/exclusion criteria were excluded.

Data Collection and Extraction

All identified records were screened independently by titles and abstracts by two reviewers (CL and PC) and validated by another reviewer (SL). The full texts of relevant articles were retrieved for further eligibility assessment, extracted, and any discrepancies were resolved through discussion. The information extracted included the author, study design and population, outcomes, and quality of the study using a standardized data extraction form. We subsequently assessed the study quality using the Cochrane risk of bias assessment tool (Higgins et al., 2011).

Outcome Measures

The co-primary outcomes of interest were the composite of mortality or major neurodevelopmental disability and/or mortality assessed at least 18 months of age. Secondary outcomes include cerebral palsy, development delay based upon the mental development and psychomotor indices of the Bayley II scales of infant development (Bayley, 1993), seizures, quality of vision and hearing, and potential adverse effects caused by the treatment.

Statistical Analyses

We used a stepwise approach whereby traditional meta-analysis was performed using the Mantel-Haenszel random-effects model...
since we expect the presence of heterogeneity. We calculated the risk ratio and risk difference for dichotomous outcomes, and its 95% confidence interval. To determine whether the benefit of treatment on outcomes was affected by the severity of encephalopathy, we examined subgroups for which the severity of encephalopathy was graded as moderate or severe on the basis of clinical examination and/or amplitude integrated electroencephalography. The consistency of the treatment effect across subgroups was explored by calculating the ratio of relative risks with 95% confidence interval. Potential small study publication bias was assessed using visual inspection of the funnel plot and Eggers test. Between studies heterogeneity was assessed using $P$ and Cochran's $Q$ method.

We subsequently performed a network meta-analysis which combines the direct and indirect effects of treatment, allowing for simultaneous comparison of multiple treatments. These were ranked using the surface under the curve ranking (SUCRA). Inconsistency checks were performed for closed loop in the network (Higgins et al., 2012; Veroniki et al., 2013). Subsequently, we calculated the number needed to treat (NNT) or number needed to harm (NNH) to better understand the potential benefits of different treatments examined. We used the odds ratios (OR) derived from the usual care comparison in network meta-analysis for mortality outcome to estimate the absolute benefits (Dulai et al., 2016).

Preplanned sensitivity analyses include comparison between high versus low-middle income countries as well as severity of encephalopathy. All analyses were conducted using Stata version 13.0 (StataCorp, College TX). This study is registered with PROSPERO, number CRD42016053390.

RESULTS

Study Selection and Characteristics

The literature search identified a total of 1,731 studies and 71 full-text articles were assessed for eligibility (Figure 1 and eTables 1 and 2). Fifteen studies enrolling 2,313 newborns were included in the review (Gluckman et al., 2005; Shankaran et al., 2005; Li et al., 2009; Zhu et al., 2009; Simbruner et al., 2010; Zhou et al., 2010; Joy et al., 2013; Azzopardi et al., 2016; Savitha and Prakash, 2016; Malla et al., 2017; Sreenivasa et al., 2017). Most of the included studies had a similar enrollment criteria and included infants with evidence of birth asphyxia as defined by the American College of Obstetrician and Gynecologists (American College of Obstetricians and Gynecologists, 2014) with moderate to severe HIE. These studies had recruited newborns which were at least 35 weeks in 1 study, at least 36 weeks in 3 studies, and gestation weeks of more than or equal to 37 weeks in 9 studies. Interventions examined by studies were therapeutic hypothermia examined in 10 studies (8 whole body cooling and 2 selective head cooling), magnesium sulfate in 2 studies, erythropoietin in 2 studies, and use of xenon with therapeutic hypothermia in 1 study (Table 1). Eight studies (53.3%) were published in 2011 or later, and the studies were conducted in India (40%), China (20%), or were multicentered studies (20%). Nine studies (60%) had a duration (from recruitment to end of follow-up) of at least 18 months or more.

Methodological Quality of Included Studies

Twelve (80.0%) studies had adequate reporting on sequence generation, 12 (80.0%) studies described the loss to follow-up, 10 (66.7%) studies described the selection concealment adequately, and 6 (40.0%) studies described the blinding of participants and outcome assessment. However, a high proportion [10 (66.7%)] had unclear risk of bias for blinding of outcome assessors (eFigure 1).

Primary Outcomes

Mortality

Fifteen RCTs reported the effectiveness of intervention in reducing the risk of mortality. Pairwise meta-analysis showed that whole body hypothermia was effective in reducing the risk of mortality (OR: 0.71; 0.52–0.92, $I^2 = 0$%) compared to usual care (Table 3).

Mortality and/or Neurodevelopmental Delay at 18 Months

Nine studies reported the long term effects of pharmacotherapy or hypothermia on mortality and neurodevelopmental delay at 18 months (Gluckman et al., 2005; Shankaran et al., 2005; Azzopardi et al., 2009; Li et al., 2009; Zhu et al., 2009; Simbruner et al., 2010; Zhou et al., 2010; Jacobs et al., 2011; Malla et al., 2017). Pooled analysis of studies suggest that both erythropoietin (OR: 0.57; 0.36–0.91, $I^2 = 0$%) and whole body hypothermia (0.74; 0.59–0.92, $I^2 = 0$%) were effective in reducing the risk of mortality and neurodevelopmental delay at 18 months.

Secondary Outcomes

Among infants who survived, 12 trials including 1,951 infants reported on cerebral palsy outcome. Whole body hypothermia was found to be statistically superior in reducing the odds developing cerebral palsy (0.70; 0.54–0.92, $I^2 = 0$%) compared to usual care. With respect to seizures, 10 trials including 1,703 infants were included. Whole body hypothermia was superior in reducing the rates of seizure compared to usual care (0.73; 0.56–0.96, $I^2 = 0$%).

Five studies reported the neuromotor delay and neurodevelopmental delay among neonates using the Bayley II index, but results were not significant. For the other outcomes of renal failure, sepsis, hypotension, hypoglycemia, bradycardia, hearing loss, and blindness, the evidence base were sparse (eTable 4). Meta-analysis suggests that therapeutic hypothermia (both whole body and selective head cooling) were associated with an increased rate of normal survival, defined as survival without cerebral palsy, seizures, normal vision, and hearing.
Effect of Severity of Encephalopathy
Most studies assessed the severity of encephalopathy by clinical assessment using Sarnat’s criteria (Sarnat and Sarnat, 1976), which classifies the degree of encephalopathy to either stages I, II or III, correlating with mild, moderate or severe encephalopathy. Pooled analysis suggests that the relative odds of mortality or neurodevelopmental disability were lower among infants with moderate encephalopathy when treated with erythropoietin (0.27; 0.11–0.63, $I^2 = 0\%$) or whole body hypothermia (0.63; 0.44–0.89, $I^2 = 0\%$). Among infants with severe encephalopathy, all interventions including erythropoietin, whole body hypothermia or selective head hypothermia was ineffective in reducing the risk of combined outcomes of mortality or neurodevelopmental disability (eTable 5).

Network Meta-Analysis
Mortality or Mortality and Neurodevelopmental Disability at 18 Months
Overall, of the 15 unique pairwise comparisons that could be made, only 5 were studied head to head. The network meta-analysis gave an adequate fit to the data and design-by-treatment model showed no evidence of inconsistency (eFigure 2).
### TABLE 1 | Characteristics of included studies.

| First Author, Year (Study) | Study Population | Interventions | Number of Patients Enrolled | Mean gestational age or age range, weeks |
|----------------------------|------------------|---------------|-----------------------------|----------------------------------------|
| **Drug Intervention as Single Treatment** | | | | |
| Malla et al., 2017 | Neonates (≥37 weeks) with moderate or severe HIE (10 min Apgar score <5) evidence of fetal distress, need for resuscitation at 10 mins after birth | I: 500 U/kg rhEPO intravenously on alternate dose for a total of 5 doses with the 1st dose within 6 hours after birth  
C: 2mL of normal saline | 100 | 39.5 |
| Zhu et al., 2009 | Term neonates (≥37 weeks), body weights >2500 g with evidence of perinatal HIE (5-min Apgar score ≤5, need for resuscitation at 10 mins after birth) | I: 300 U/kg or 500 U/kg rhEPO subcutaneously for 1st dose and intravenously every other day for 2 weeks  
C: Conventional treatment | 167 | 37.5 |
| Savitha and Prakash, 2016 | Term neonates with perinatal asphyxia, 1-min Apgar score <7, need for resuscitation at birth, failure to initiate breath at birth | I: 250 mg/kg MgSO₄ intravenous infusion over 1 h within 6 h of birth, with additional doses repeated at 24 h and 48 h  
C: Supportive care | 120 | 38.6 |
| Sreenivasa et al., 2017 | Term neonates with perinatal asphyxia, 1-min Apgar score <3 or 5-min Apgar score <6 | I: 250 mg/kg MgSO₄ intravenous infusion over 1 h within 6 h of birth, with additional doses repeated at 24 h and 48 h  
C: Supportive care | 100 | 38.7 |
| Azzopardi et al., 2009 (TOBY) | Term neonates (≥36 gestation weeks) with moderate to severe HIE, Apgar score <6, seizure on aEEG | I: Manually adjusted cooling blanket to target rectal temperature of 33.0°C–34.0°C for 72 hr  
C: Conventional care with overhead radiant heater to target rectal temperature of 36.8°C–37.2°C | 325 | 38.8–41.3¹ |
| Bharadwaj, 2012 | Term neonates (>37 gestation weeks) with perinatal asphyxia (10-min Apgar score ≤8), and encephalopathy | I: Whole body cooling with gel packs to target rectal temperature of 33.0°C–34.0°C  
C: Conventional care with servo-controlled overhead radiant heater to target rectal temperature of 36.5°C | 130 | 40.0 |
| **Cooling (Whole body)** | | | | |
| Gane, 2013 | Term neonates (≥37 weeks) with evidence of encephalopathy (10-min Apgar <5) | I: Cloth covered gel packs to target rectal temperature of 33°C–34°C for 72 h  
C: Conventional care for HIE to target of 36.5°C | 122 | 40.1 |
| Jacobs et al., 2011 (ICE) | Term or near term neonates (≥35 gestation weeks) with moderate to severe HIE, perinatal asphyxia, 10-min Apgar score <6 | I: Refrigerated gel pack across chest and/or under head and shoulders to target rectal temperature of 33.0°C–34.0°C for 6–72 h  
C: Conventional care with overhead radiant heater to target rectal temperature of 36.8°C–37.2°C | 221 | 39.1 |
| Joy et al., 2013 | Term neonates (≥37 weeks) with evidence of encephalopathy (10-min Apgar ≤5) | I: Cloth covered gel packs to target rectal temperature of 33–34 ºC for 72 h  
C: Conventional care for HIE to target rectal temperature of 36.5°C | 160 | - |
| Li et al., 2009 | Term neonates (≥37 weeks), weight >2500 g, with moderate to severe encephalopathy (5-min Apgar ≤5) | I: Whole body cooling with cooling mattress to target rectal temperature of 33°C–34°C for 72 h  
C: Conventional care for HIE to target rectal temperature of 36.5°C–37.5°C | 93 | 39.1 |

(Continued)
### TABLE 1 | Continued

| First Author, Year (Study) | Study Population | Interventions | Number of Patients Enrolled | Mean gestational age or age range, weeks |
|----------------------------|------------------|---------------|----------------------------|-----------------------------------------|
| Shankaran et al., 2005 (NICHD study) | Term neonates (≥37 gestation weeks) with moderate to severe HIE, perinatal asphyxia (10 min Apgar score ≤5) | I: Two servo-controlled cooling blanket to target oesophageal temperature of 34.5 °C for 72 h<br>C: Conventional care with overhead radiant heater to target skin temperature of 36.5 °C–37.0 °C | 208 | 4.3 h* |
| Simbruner et al., 2010 (neo,nEURO) | Term neonates (≥36 gestation weeks) with moderate to severe HIE, perinatal asphyxia (10 min Apgar score ≤5) and encephalopathy as evidence by abnormal standard EEG or aEEG findings | I: Cooling blanket to target rectal temperature of 33.0 °C–34.0 °C for 72 h<br>C: Conventional care to target rectal temperature of 36.5 °C–37.5 °C | 129 | 39.3 |
| Gluckman et al., 2005 (CoolCap) | Term neonates (≥37 gestation weeks) with moderate to severe HIE, perinatal asphyxia, 10-min Apgar score ≤5, severe acidosis (pH < 7) or a base deficit of 16 mmol/L | I: Manual controlled cooling cap to target temperature of 34.0 °C–35.0 °C for 72 h<br>C: Conventional care with overhead radiant heater to target of 36.5 °C–37.5 °C | 234 | 39.0 |
| Zhou et al., 2010 | Term neonates (≥37 gestation weeks) with perinatal asphyxia (5-min Apgar score ≤5 or 1-min Apgar score ≤3), birth weight ≥2500 g, and encephalopathy | I: Manually controlled cooling cap to rectal target temperature of 34.5 °C–35.0 °C for 72 h<br>C: Conventional care whereby infants are cared on radiant warmers servo-controlled to rectal target of 36.0 °C–37.5 °C | 194 | 4.0 h* |
| Gluckman et al., 2005 (CooCap) | Term neonates (≥37 gestation weeks) with moderate to severe HIE, perinatal asphyxia, 10-min Apgar score ≤5, and severe abnormalities of background activity for ≥30 min or seizures shown by aEEG, 10-min Apgar score ≤5, continued need for resuscitation for ≥10 min | I: Whole body hypothermia to target rectal temperature of 33.5 °C plus 30% inhaled xenon for 24 h<br>C: Whole body hypothermia alone to target rectal temperature of 33.5 °C | 92 | 39.8 |

AAP, American Association of Pediatrics; ACOG, American College of Obstetricians and Gynecologists; aEEG, amplitude-integrated continuous electroencephalopathy; C, control group; CBV, cerebral blood volume; EAA, excitatory amino acids; EPO, erythropoietin; 1st, first; I, intervention group; h, hours; HIE, hypoxic-ischemic encephalopathy; MgSO₄, magnesium sulfate; min, minutes; m, months; NaCl, normal saline; NO, nitric oxide; rhEPO, recombinant human erythropoietin; subcut, subcutaneously.

* Age at randomization; †Interquartile range.

### TABLE 2 | Network meta-analysis for primary outcomes mortality.

| Drug Intervention as Adjuvant | Whole body hypothermia | Selective head hypothermia | Erythropoietin | Magnesium sulfate | Whole body hypothermia with xenon | Usual care |
|------------------------------|-------------------------|---------------------------|--------------|-----------------|----------------------------------|-----------|
| Xenon                        | 1.11 (0.59, 2.08)       | 0.78 (0.20, 3.14)         | 1.18 (0.24, 5.96) | 1.17 (0.30, 4.55) | 0.80 (0.28, 2.26) |
|                              | 0.66 (0.26, 1.67)       | 0.92 (0.22, 3.83)         | 0.99 (0.18, 5.45) | 0.93 (0.39, 2.25) | 0.79 (0.20, 3.06) |
|                              | 0.77 (0.29, 2.09)       | 0.91 (0.30, 2.79)         | 0.93 (0.28, 3.54) | 0.73 (0.48, 1.11) | 0.80 (0.28, 2.26) |

Comparisons should be read from left to right. The estimate is located at the intersection of the column-defining treatment and the row-defining treatment. An OR value below 1 favors the column-defining treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Any significant results are in bold and underlined.
All interventions examined showed a reduction in risk of mortality compared to usual care (Figure 2, Table 2 and eTable 6). However, only whole body hypothermia was significantly better than usual care (0.62; 0.46–0.83), with an NNT of 11 (95% CI: 7–26) in reducing the risk of mortality. With respect to the composite mortality or neurodevelopmental disability outcome at 18 months or longer, erythropoietin was significantly better than usual care in patients with moderate encephalopathy (0.36; 0.19–0.66; Figure 3). Therapeutic hypothermia (both whole body and selective head cooling) was the only treatment statistically superior to usual care in patients with moderate (whole body: 0.45; 0.31–0.66 and selective head: 0.51; 0.29–0.89) or severe encephalopathy (whole body: 0.32; 0.12–0.86).

Secondary Outcomes

Network meta-analysis suggest that, compared to usual care, treatment with either erythropoietin or whole body hypothermia were associated with lower rates of cerebral palsy (0.36; 0.18–0.74 and 0.61; 0.45–0.83, respectively) and seizures (0.35; 0.13– 0.94 and 0.64; 0.46–0.87, Figure 3).

Sensitivity Analyses

Comparison-adjusted funnel plots of the network meta-analysis for primary outcomes did not suggest any publication bias (eFigure 4). Ranking of treatment based upon cumulative probability plots (eFigure 5) and SUCRA showed that the most effective treatment for primary outcome mortality was whole body hypothermia (77.8%) and the least effective was usual care (24.5%). In terms of the composite outcome of mortality or neurodevelopmental disability at 18 months, the most effective treatment was erythropoietin (88.8%) and the least effective was usual care (0.2%). Using GRADE, the quality of evidence for primary outcomes were moderate to very low for most comparison (Table 3 and eTable 8).

In the preplanned sensitivity analyses, we excluded studies which were conducted in low-middle income countries since previous meta-analysis have suggested that these study setting could influence the results (Pauliah et al., 2013). When studies from high-income countries were only included, only three comparisons were possible for the outcome of mortality. Results from the network meta-analysis was largely unchanged, and whole body cooling was found to reduce the risk of mortality by 36% (0.64; 0.46–0.90) as well as mortality or major neurodevelopmental disability at 18 months by 49% (0.51; 0.33–0.78) compared to usual care. These results were largely unchanged when we included studies which had examined full term neonates (>37 weeks), where whole body cooling reduced the risk of mortality (0.50; 0.31–0.81) as well as mortality or major neurodevelopmental disability at 18 months (0.44; 0.27–0.71) compared to usual care (eTable 9). In addition, selective

| Intervention | Odds ratio (95% credible interval) |
|--------------|----------------------------------|
| Mortality    |                                  |
| WBH          | 0.62 (0.46, 0.83)                |
| SHH          | 0.73 (0.48, 1.11)                |
| EPO          | 0.93 (0.39, 2.25)                |
| MgS          | 0.79 (0.28, 2.26)                |
| Xe+WBH       | 0.80 (0.28, 2.26)                |
| Mortality and/or disability at 18 months | |
| WBH          | 0.54 (0.32, 0.89)                |
| SHH          | 0.49 (0.33, 0.72)                |
| EPO          | 0.36 (0.19, 0.66)                |

**FIGURE 2** Network meta-analysis forest plots for each treatment versus usual care on mortality or mortality and neurodevelopmental delay at 18 months outcome. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects; an OR >1 suggests that usual care is more effective to reduce the risk of mortality, whereas an OR <1 suggests that the comparable treatment is better. The vertical blue line corresponds to an OR=1.
FIGURE 3 | Network meta-analysis forest plots for each treatment versus usual care on secondary outcomes. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects; an odds ratio > 1 suggests that usual care is more effective to reduce the risk of mortality, whereas an OR< 1 suggests that the comparable treatment is better. The vertical blue line corresponds to an OR=1.
TABLE 3 | Summary of findings table for the primary outcomes assessed in this study.

| Estimates of effects, credible intervals, and certainty of the evidence for comparison of neuroprotective therapies for neonates with hypoxic ischemic encephalopathy |
|---|
| **Patient or population:** Neonates with hypoxic ischemic encephalopathy |
| **Interventions:** Whole body cooling, selective head cooling, magnesium sulfate, erythropoietin, whole body cooling with xenon |
| **Comparator (reference):** Usual care |
| **Outcome:** Mortality; mortality or neurodevelopmental disability at 18 months or later |
| **Setting(s):** Inpatient and outpatient |

| Geometry of the Network |
|---|
| **Total studies:** 15 RCT |
| **Total Participants:** 2,103 |

| Odds ratio (95% CrI) | Anticipated absolute effect (95% CrI) | Certainty of the evidence | Interpretation of Findings |
|---|---|---|---|
| **Mortality** |
| Whole body cooling | 0.62 (0.46 to 0.83) | 261 per 1,000 | 81 fewer per 1,000 |
| Direct evidence; 8 RCT; 1324 participants | 180 per 1,000 | (from 121 fewer to 34 fewer) |
| Selective head cooling | 0.73 (0.48 to 1.11) | 259 per 1,000 | 56 fewer per 1,000 |
| Direct evidence; 2 RCT; 428 participants | 204 per 1,000 | (from 115 fewer to 21 more) |
| Magnesium sulfate | 0.79 (0.20 to 3.06) | 36 per 1,000 | 7 fewer per 1,000 |
| Direct evidence; 2 RCT; 220 participants | 29 per 1,000 | (from 29 fewer to 67 more) |
| Erythropoietin | 0.93 (0.39 to 2.25) | 89 per 1,000 | 6 fewer per 1,000 |
| Direct evidence; 2 RCT; 253 participants | 84 per 1,000 | (from 53 fewer to 92 more) |
| Whole body cooling with xenon | 0.80 (0.28 to 2.26) | 196 per 1,000 | 33 fewer per 1,000 |
| Direct evidence; 1 RCT; 92 participants | 163 per 1,000 | (from 132 fewer to 159 more) |

| Mortality or neurodevelopmental delay at 18 months |
|---|---|---|---|
| Whole body cooling | 0.54 (0.32 to 0.89) | 607 per 1,000 | 152 fewer per 1,000 |
| Direct evidence; 5 RCT; 934 participants | 455 per 1,000 | (from 276 fewer to 28 fewer) |
| Selective head cooling | 0.49 (0.33 to 0.72) | 583 per 1,000 | 176 fewer per 1,000 |
| Direct evidence; 2 RCT; 412 participants | 407 per 1,000 | (from 267 fewer to 81 fewer) |
| Erythropoietin | 0.36 (0.29 to 0.67) | 538 per 1,000 | 243 fewer per 1,000 |
| Direct evidence; 2 RCT; 253 participants | 296 per 1,000 | (from 286 fewer to 100 fewer) |

1 Study was downgraded due to imprecision and lack of direct RCTs contributing to direct evidence; 2 Few event rates with wide confidence intervals leading to imprecision; 3 Serious indirectness; 4 Contributing direct evidence of moderate quality with inadequate concealment of allocation and blinding.

Interpretation of Findings:
- Whole body cooling improves survival in newborns with HIE
- Selective head cooling probably improves survival in newborns with HIE
- Use of magnesium sulfate has limited effect on survival in newborns with HIE
- Use of erythropoietin probably improves survival and neurodevelopment in newborns with HIE
- Use of xenon as an adjuvant with whole body cooling has limited effect on survival in newborns with HIE
- Whole body cooling improves survival and neurodevelopment in newborns with HIE
- Selective head cooling probably improves survival and neurodevelopment in newborns with HIE
- Use of erythropoietin probably improves survival and neurodevelopment in newborns with HIE
DISCUSSION

In this study, direct and indirect evidence from 15 RCTs was combined to compare the association of each therapy used for neuroprotection in HIE. The study has several key findings. Firstly, therapeutic hypothermia was significantly associated with lower odds of mortality and neurodevelopmental delays compared to usual care, with high confidence estimates and a number to treat of between 11 and 16. Secondly, whole body hypothermia should be offered to all infants with HIE, irrespective of the severity as it was effective in reducing the risk of morbidity as well as neurodevelopmental delays when compared to usual care.

Over the past decade, numerous drugs have been proven useful to be beneficial in animal models for neonates with HIE, but how these can be translated into clinical use remains unknown (Nair and Kumar, 2018). Our study provides novel insights into how different neuroprotective agents could be useful in patients with HIE especially when used in combination with hypothermia (Martinello et al., 2017). Although there is much progress, further studies are needed to determine the effectiveness of these adjuvant therapies. Several large clinical studies are underway to examine the benefits of these neuroprotective agents.

A previous review suggested that key differences exist in terms of efficacy between high-income and low-middle income countries, due to the use of low-technology devices, degree of encephalopathy, maternal pre-existing diseases, malnutrition status, infections, as well as study inclusion criteria (Pauliah et al., 2013). In this study, we showed that therapeutic hypothermia especially whole body hypothermia was the most effective intervention irrespective of study setting as well as device used. As HIE is the major cause of up to 23% of 2.8 million neonatal deaths especially in low-resource setting, our findings provide a further impetus for therapeutic hypothermia to be part of standard of care in low-middle income countries.

Our findings support the Cochrane review on hypothermia in patients with HIE for the primary outcome, where we found that cooling was beneficial in reducing the risk of mortality and disability (Jacobs et al., 2013). This has similarly been reported by other authors which concluded that hypothermia improves survival and neurodevelopmental delays in newborns (Tagin et al., 2012; Douglas-Escobar and Weiss, 2015). The current review was larger (an additional 4 RCTs and 808 infants) and includes information on the effectiveness of different neuroprotective agents. While the authors of a recent systematic review on hypothermia did not conduct network meta-analysis, the results presented were similar to those reported here and suggest that therapeutic hypothermia is effective.

Study Strength

Strengths of our review are that we conducted a comprehensive search as well as the identification of new additional studies. We also used multiple approaches to assess the relationship of effects and performed a network meta-analysis, which provides added information on effects of different combination of interventions (drugs and non-drugs). The quality of the evidence generated were rated using the GRADE criterion (Puhan et al., 2014). We used a comprehensive search strategy and searched all pertinent sources for eligible studies, which reduces the possibility of missing any relevant studies. This study also included preterm infants ≥35 weeks as part of the inclusion criteria and provides a more holistic overview on the clinical safety and efficacy of therapeutic hypothermia in this group of infants where data on outcomes are sparse. Nevertheless, these results need to be confirmed from larger randomized controlled trials such as the Premmie Hypothermia for Neonatal Encephalopathy study which is currently in progress (NCT01793129). Until then, clinicians should take precaution especially when treating preterm neonates since evidence from a recent retrospective cohort analysis have suggested that a high incidence of complication and composite outcome of death and neurodevelopmental impairment (Herrera et al., 2018).

Study Limitations

The limitations of our review are the inherent heterogeneity in terms of study design, intervention, as well as outcome assessment of included studies. We attempted to minimize this by using rigorous selection criteria and performing several sensitivity analyses to ensure the robustness of our results. Secondly, analysis for other outcomes such as neurodevelopmental outcomes, blindness, as well as adverse events should be interpreted with caution, owing to the few data points available. However, a recent high quality long-term study on effects of depth and duration of cooling showed that there is little to no effect of different hypothermia therapy or duration of therapy on outcome (Shankaran et al., 2014; Laptook et al., 2017). This independent analysis reinforces the case that hypothermia should be standard therapy, and additional policy options may be needed in low resource settings to improve outcomes. As with most network meta-analyses, there were only sparse data for some of the treatment comparison especially those related to erythropoietin, and thus, it is recommended that these treatment effect estimates be interpreted together with their precision.

Our study also revealed that additional studies are needed to further optimize cooling therapy as well as rewarming methods, such as the recently concluded NICHD funded study which examined the impact of different cooling depth and duration in neonates with HIE (Shankaran et al., 2014; Laptook et al., 2017). In addition, sufficiently powered studies which examine the use of adjuvant therapies in addition to hypothermia are needed. Another research goal is to reliably identify for subgroups of newborns who will go on to develop worsening encephalopathy and significant brain injury, possibly through the use of electroencephalography, or other biomarker to ensure that they benefit most from hypothermia. In summary, results of our analysis generally support current guidelines using hypothermia for neonates with HIE irrespective of setting. Our findings further support whole body hypothermia as first line, due to its ease of use, improving.
mortality and neurodevelopmental outcomes. However, further research is needed to determine if the use of additional adjuvant therapies could further improve outcomes of HIE.

**DATA AVAILABILITY STATEMENT**

All datasets generated and analysed in this study are included in the article/Supplementary Material.

**AUTHOR CONTRIBUTIONS**

SL conceptualized the study, designed the data collection instrument, carried out the statistical analysis, drafted the initial manuscript, and reviewed and revised the manuscript. CL and PC carried out the data acquisition and helped draft out the initial manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**REFERENCES**

Aly, H., Elmahdy, H., El-Dib, M., Rowisha, M., Awny, M., El-Gohary, T., et al. (2015). Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. *J. Perinatol.* 35, 186. doi: 10.1038/jp.2014.186

American College of Obstetricians and Gynecologists, and American Academy of Pediatrics. (2014). Neonatal encephalopathy and neurologic outcome, second edition. *Obstet. Gynecol.* 123, 986–901. doi: 10.1097/01.AOG.0000443580.65983.d2

Azizpardi, D., Robertson, N. I., Bainbridge, A., Cady, E., Charles-Edwards, G., Deierl, A., et al. (2016). Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. *Lancet Neurol.* 15, 145–153. doi: 10.1016/S1474-4422(15)00347-6

Azizpardi, D. V., Strohm, B., Edwards, A. D., Dyel, L., Halliday, H. L., Juszczak, E., et al. (2009). Moderate hypothermia to treat perinatal asphyxial encephalopathy. *N. Engl. J. Med.* 361, 1349–1358. doi: 10.1056/NEJMoat0900854

Bayley, N. (1993). *Bayley scales of infant and development- second edition*. San Antonio, TX: Psychological Corporation.

Bharadwaj, S. K., and Vishnu Bhat, B. (2012). Therapeutic hypothermia using gel packs for term neonates with hypoxic ischaemic encephalopathy in resource-limited settings: a randomized controlled trial. *J. Trop. Pediatr.* 58(5), 382–388.

Bhat, M. A., Charoo, B. A., Bhat, J. I., Ahmad, S. M., Ali, S. W., and Mufti, M.-U.-H. (2009). Magnesium sulphate in severe perinatal asphyxia: a randomized, placebo-controlled trial. *Pediatrics* 123, e764–e769. doi: 10.1542/peds.2007-3642

Bukhsh, A., Khan, M. T., Lee, S. W. H., Lee, L.-H., Chan, K.-G., and Goh, B.-H. (2018). Efficacy of pharmacist based diabetes educational interventions on clinical outcomes of adults with type 2 diabetes mellitus: a network meta-analysis. *Front. Pharmacol.* 9. doi: 10.3389/fphar.2018.00339

Douglas-Escobar, M., and Weiss, M. D. (2015). Hypoxic-ischemic encephalopathy: a review for the clinician. *JAMA Pediatr.* 169, 397–403. doi: 10.1001/jamapediatrics.2014.3269

Dulai, P. S., Singh, S., Marquez, E., Khera, R., Prokop, L. J., Limburg, P. J., et al. (2016). Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. *BMJ* 355, i6188. doi: 10.1136/bmj.i6188

Edwards, A. D., Brocklehurst, P., Gunn, A. J., Halliday, H., Juszczak, E., Levene, M., et al. (2010). Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. *BMJ* 340. doi: 10.1136/bmj.c663

Filipp, L., Fiorini, P., Catarsi, S., Berti, E., Padrini, L., Landucci, E., et al. (2017). Safety and efficacy of topiramate in neonates with hypoxic ischaemic encephalopathy treated with hypothermia (NeoNATI): a feasibility study. *J. Matern. Fetal. Neonatal. Med.* 31(8), 973–80.

Gane, B. D., Bhat, V., Rao, R., Nandhakumar, S., Harichandarakumar, K. T. and Adhisivam, B. (2013). Effect of therapeutic hypothermia on DNA damage and neurodevelopmental outcome among term neonates with perinatal asphyxia: a randomized controlled trial. *J. Trop. Pediatr.* 60(2), 134–140.

Glickman, P. D., Wyatt, J. S., Azizpardi, D., Ballard, R., Edwards, A. D., Ferriero, D. M., et al. (2005). Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet* 365, 663–670. doi: 10.1016/S0140-6736(05)67946-X

Graham, E. M., Ruis, K. A., Hartman, A. L., Northington, F. J., and Fox, H. E. (2008). A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. *Am. J. Obstet. Gynecol.* 199, 587–595. doi: 10.1016/j.ajog.2008.06.094

Herrera, T. L., Edwards, L., Malcolm, W. F., Smith, P. B., Fisher, K. A., Pirzoli, C., et al. (2018). Outcomes of preterm infants treated with hypothermia for hypoxic-ischemic encephalopathy. *Early Hum. Dev.* 125, 1–7. doi: 10.1016/j.earlhumdev.2018.08.003

Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 343, d5928. doi: 10.1136/bmj.d5928

Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., and White, I. R. (2012). Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 3, 98–110. doi: 10.1002/jsm.1044

Jacobs, S. E., Berg, M., Hunt, R., Tarnow-Mordi, W. O., Inger, T. E., and Davis, P. G. (2013). Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev.* 165 (8). doi: 10.1002/14651858.CD003311.pub3

Jacobs, S. E., Morley, C. J., Inger, T. E., Stewart, M. J., Smith, K. R., Mcnamara, P. J., et al. (2011). Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. *Arch. Pediatr. Adolesc. Med.* 165, 692–700. doi: 10.1001/archpediatrics.2011.43

Joy, R., Pourmami, E., Bethou, A., Bhat, V. B., and Bobby, Z. (2013). Effect of therapeutic hypothermia on oxidative stress and outcome in term neonates with perinatal asphyxia: a randomized controlled trial. *J. Trop. Pediatr.* 59, 17–22. doi: 10.1093/troped/fto036

Laptopk, A. R., Shankaran, S., Tyson, J. E., Munoz, B., Bell E. F., Goldberg, R. N., et al. (2017). Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial. *JAMA* 318, 1550–1560. doi: 10.1001/jama.2017.14972

Lee, S. W.-H., Chaiyakunapruk, N., Chong, H.-Y., and Liong, M.-L. (2015). Comparative effectiveness and safety of various treatment procedures for lower pole renal calciu: a systematic review and network meta-analysis. *BJU Int.* 116, 252–264. doi: 10.1111/bju.12983

Lee, S. W. H., Chan, C. K. Y., Chua, S. S., and Chaiyakunapruk, N. (2017). Comparative effectiveness of telemendic strategies on type 2 diabetes management: a systematic review and network meta-analysis. *Sci. Rep.* 7, 12680. doi: 10.1038/s41598-017-12987-z

Li, T., Xu, F., Cheng, X., Guo, X., Ji, L., Zhang, Z., et al. (2009). Systemic hypothermia induced within 10 hours after birth improved neurological

**ACKNOWLEDGMENTS**

We wish to thank Dr. Nai Ming Lai of Taylor’s University for helping edit the manuscript for clarity, Dr. Mohamed Tagin of University of Toronto, and Dr. Seetha Shankaran of Wayne State University School of Medicine for providing input and advice on this article.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fphar.2019.01221/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fphar.2019.01221/full#supplementary-material)
outcome in newborns with hypoxic-ischemic encephalopathy. *Hosp. Pract.* 37, 147–152. doi: 10.3810/hp.2009.12.269

Malla, R., Asimi, R., Teli, M., Shaheen, E., and Bhat, M. (2017). Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. *J. Perinatol.* 37, 596–601. doi: 10.1038/jp.2017.17

Martinello, K., Hart, A. R., Yap, S., Mitra, S., and Robertson, N. J. (2017). Management and investigation of neonatal encephalopathy: 2017 update. *Arch. Dis. Child. Fetal Neonatal Ed.* 2015-309639. 102(4) doi: 10.1136/archdischild-2015-309639

Nair, J., and Kumar, V. H. S. (2018). Current and emerging therapies in the management of hypoxic-ischemic encephalopathy in neonates. *Children (Basel, Switzerland)* 5, 99. doi: 10.3390/children5070099

Pauflah, S. S., Shankaran, S., Wade, A., Cady, E. B., and Thayyl, S. (2013). Therapeutic hypothermia for neonatal encephalopathy in low- and middle-income countries: a systematic review and meta-analysis. *PLoS One* 8, e58834. doi: 10.1371/journal.pone.0058834

Perrone, S., Stazzoni, G., Tataranno, M. L., and Buonocore, G. (2012). New pharmacologic and therapeutic approaches for hypoxic-ischemic encephalopathy in the newborn. *J. Matern. Fetal. Neonatal. Med.* 25, 83–88. doi: 10.3109/14767058.2012.663168

Puhan, M. A., Schünemann, H. J., Murad, M. H., Li, T., Brigandello-Petersen, R., Singh, J. A., et al. (2014). A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *Br. Med. J.* 349. doi: 10.1136/bmj.g5630

Sarnat, H. B., and Sarnat, M. S. (1976). Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. *Arch. Neurol.* 33, 696–705. doi: 10.1001/archneurol.1976.00500100300012

Savitha, M. R., and Prakash, R. (2016). Beneficial effect of intravenous magnesium sulphate in term neonates with perinatal asphyxia. *Int. J. Contemp. Pediatr.* 3, 150–154. doi: 10.18203/2349-3291.jcp20160149

Shankaran, S., Laptook, A. R., Ehrenkranz, R. A., Tyson, J. E., McDonald, S. A., Donovan, E. F., et al. (2005). Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. *N. Engl. J. Med.* 353, 1574–1584. doi: 10.1056/NEJMc050929

Shankaran, S., Laptook, A. R., Pappas, A., McDonald, S. A., Das, A., Tyson, J. E., et al. (2014). Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial. *JAMA* 312, 2629–2639. doi: 10.1001/jama.2014.16058

Shankaran, S., Laptook, A. R., Pappas, A., McDonald, S. A., Das, A., Tyson, J. E., et al. (2017). Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial. *JAMA* 318, 57–67. doi: 10.1001/jama.2017.7218

Simbruner, G., Mittal, R. A., Rohllmann, F., and Muche, R. (2010). Systemic hypothermia after neonatal encephalopathy: outcomes of neo. nEURO. network RCT. *Pediatrics* 2009–2441. doi: 10.1542/peds.2009-2441d

Sreenivasa, B., Lokeshwarli, K., and Joseph, N. (2017). Role of magnesium sulphate in management and prevention of short term complications of birth asphyxia. *Sri Lanka J. Child Health* 46, 148–151. doi: 10.4038/sljch.v46i2.8271

Tagin, M. A., Woolcott, C. G., Vincer, M. J., Whyte, R. K., and Stinson, D. A. (2012). Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. *Arch. Pediatr. Adolesc. Med.* 166, 558–566. doi: 10.1001/archpediatrics.2011.1772

Teoh, K. W., Khan, T. M., Chatyakunapruk, N., and Lee, S. W. H. (2019). Examining the use of network meta-analysis in pharmacy services research: a systematic review. *J. Am. Pharm. Assoc.* doi: 10.1016/j.japh.2019.06.015

Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., and Salanti, G. (2013). Evaluation of inconsistency in networks of interventions. *Int. J. Epidemiol.* 42, 332–345. doi: 10.1093/ije/dys222

Watt, J., Tricco, A. C., Straus, S., Veroniki, A. A., Naglie, G., and Drucker, A. M. (2019). Research techniques made simple: network meta-analysis. *J. Investig. Dermatol.* 139, 4–12.e11. doi: 10.1016/j.jid.2018.10.028

Zhou, W.-H., Cheng, G.-Q., Shao, X.-M., Liu, X.-Z., Shan, R.-B., Zhuang, D.-Y., et al. (2010). Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy: a multicenter randomized controlled trial in China. *J. Pediatr.* 157, 367–372. e563. doi: 10.1016/j.jpeds.2010.03.030

Zhu, C., Kang, W., Xu, F., Cheng, X., Zhang, Z., Jia, L., et al. (2009). Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. *Pediatrics* 124, e218–e226. doi: 10.1542/peds.2008-3553

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor and reviewer, BG, declared their involvement as co-editors in the Research Topic, and confirm the absence of any other collaboration.

Copyright © 2019 Lee, Chakranon and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.